KW
Kwangdong Healthbio Co., Ltd.
086220 | KO
Overview
Corporate Details
- ISIN(s):
- KR7086220001
- LEI:
- Country:
- South Korea
- Address:
- 충청북도 청원군 오창읍 양청송대길 39(송대리), 오창읍
- Website:
- http://www.kd-healthbio.com
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-06-04 00:00 |
Report Publication Announcement
기업설명회(IR)개최결과
|
Korean | 6.7 KB | ||
| 2025-05-21 00:00 |
Report Publication Announcement
기업설명회(IR)개최
|
Korean | 7.1 KB | ||
| 2025-03-25 00:00 |
AGM Information
정기주주총회결과
|
Korean | 15.2 KB | ||
| 2025-03-17 00:00 |
Audit Report / Information
감사보고서제출
|
Korean | 9.6 KB | ||
| 2025-03-17 00:00 |
Annual / Quarterly Financial Statement
사업보고서 (2024.12)
|
Korean | 436.1 KB | ||
| 2025-03-10 00:00 |
Pre-Annual General Meeting Information
주주총회소집공고
|
Korean | 114.1 KB | ||
| 2025-02-25 00:00 |
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
|
Korean | 26.1 KB | ||
| 2025-02-25 00:00 |
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
|
Korean | 25.1 KB | ||
| 2025-02-25 00:00 |
Pre-Annual General Meeting Information
주주총회소집결의
|
Korean | 8.4 KB | ||
| 2025-02-25 00:00 |
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
|
Korean | 28.6 KB | ||
| 2024-12-11 00:00 |
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
|
Korean | 4.4 KB | ||
| 2024-10-30 00:00 |
Report Publication Announcement
기업설명회(IR)개최결과
|
Korean | 6.7 KB | ||
| 2024-10-14 00:00 |
Report Publication Announcement
기업설명회(IR)개최
|
Korean | 7.0 KB | ||
| 2024-08-20 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
|
Korean | 53.3 KB | ||
| 2024-08-19 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
|
Korean | 53.6 KB |
Automate Your Workflow. Get a real-time feed of all Kwangdong Healthbio Co., Ltd. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Kwangdong Healthbio Co., Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Kwangdong Healthbio Co., Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America
950130
United States of America
950130
Developing cytisinicline, a plant-based treatment for smoking cessation and nicotine addiction.
United States of America
ACHV
United States of America
ACHV
Developing precision medicine to diagnose, treat, and prevent neurodegenerative diseases.
United States of America
ACIU
United States of America
ACIU
A clinical-stage biopharma developing novel drugs for immuno-inflammatory diseases.
United States of America
ACRS
United States of America
ACRS
Develops precision cancer therapies by matching patients to drugs using its proteomics platform.
United States of America
ACRV
United States of America
ACRV
Clinical-stage biopharma developing a first-in-class drug for thrombotic diseases like stroke.
France
ALACT
France
ALACT
Develops targeted radiotherapies for advanced cancers like AML and prostate cancer.
United States of America
ATNM
United States of America
ATNM
Clinical-stage biopharma developing a novel GSK-3 inhibitor for hard-to-treat cancers.
United States of America
ACTU
United States of America
ACTU
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden
ACUC
Sweden
ACUC
Clinical-stage biopharma developing an antibody therapy for Alzheimer's by targeting toxic AβOs.
United States of America
ABOS
United States of America
ABOS